EGFRvIII

EGFRvIII 분자 정보

영어 이름Epidermal growth factor receptor variant III시판 약물 수0
임상 약물 수14표적 별명
최고 연구 개발 단계Phase 2 Clinical
영어 이름Epidermal growth factor receptor variant III
표적 별명
시판 약물 수0
임상 약물 수14
최고 연구 개발 단계Phase 2 Clinical

EGFRvIII분자 배경

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
WSD-0922WSD0922; WSD-0922Phase 2 ClinicalWayshine Biopharm International LtdAstrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma
상세
Anti-EGFRvIII-CAREGFRvIII CAR; Anti-EGFRvIII-CARPhase 2 ClinicalKite Pharma, National Cancer InstituteBrain Neoplasms; Glioblastoma; Glioma; Gliosarcoma
상세
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)CPGJ-602; 602; CPGJ602; CPGJ 602Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdColorectal Neoplasms
상세
WSD-0922-FUWSD0922-FU; WSD-0922-FUPhase 2 ClinicalWayshine Biopharm International LtdAstrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lung Neoplasms; Neoplasms; Solid tumours
상세
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)LXF-821Phase 1 ClinicalNovartis Pharma Ag, University Of PennsylvaniaGlioblastoma
상세
EGFRvIII-CARPhase 1 ClinicalDuke University Medical CenterGlioblastoma
상세
Metabolically Armed EGFRvIII CAR-T cells therapy (Leman Biotech)Meta10-EGFRvIII; LMC005Phase 1 ClinicalLeman Biotech Co LtdGlioblastoma
상세
APTN-101CBRX-101; APTN 101Phase 1 ClinicalAdaptin Bio IncGlioblastoma; Glioma
상세
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)Phase 1 ClinicalCalifornia Institute For Regenerative Medicine, National Cancer InstituteGlioblastoma
상세
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY)DCTY0801; DCTY-0801Phase 1 ClinicalBeijing DCTY Biotech Co LtdGlioblastoma; Glioma
상세
SNC-109SNC109; SNC-109Phase 1 ClinicalShanghai Simnova Biotechnology Co LtdGlioblastoma
상세
RO-7428731RO-7428731; RG-6156Phase 1 ClinicalF. Hoffmann-La Roche LtdGlioblastoma
상세
GNC-039GNC-039Phase 1 ClinicalSichuan Baili Pharmaceutical Co LtdGlioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours
상세
89Zr-ABT806ClinicalHuashan HospitalGlioma
상세
  • 분자 정보
  • 제품 목록
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호